Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dung Nguyen

Internal Medicine Tucson, AZ Doctor of Osteopathy

NPI 1023057700 CMS profile 227312

7340 E Speedway Blvd, Suite 101, Tucson, AZ 85710

Open in the dashboard

General payments

$7,132

435 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dung Nguyen of Tucson, AZ is reported in the CMS Open Payments database as having received $7,132 across 435 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $440 23
2024 General $1,387 67
2023 General $905 54
2022 General $1,172 69
2021 General $1,320 88
2020 General $1,165 83
2019 General $741 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dung Nguyen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dung Nguyen were reported at $440. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dung Nguyen Internal Medicine median Middle half National median
2019 $741 $159 $48–$570 $163
2020 $1,165 $119 $33–$402 $114
2021 $1,320 $135 $37–$521 $132
2022 $1,172 $141 $42–$496 $149
2023 $905 $149 $45–$519 $160
2024 $1,387 $154 $47–$537 $164
2025 $440 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $934 67 payments
  2. AstraZeneca Pharmaceuticals LP $929 45 payments
  3. Novo Nordisk Inc $860 67 payments
  4. Amgen Inc. $518 31 payments
  5. Lilly USA, LLC $438 27 payments
  6. AbbVie, Inc. $367 23 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $353 22 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $236 13 payments
  9. Amarin Pharma Inc. $233 14 payments
  10. Sanofi-Aventis U.S. LLC $214 13 payments
  11. Other $2,049 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,083 431 payments
  2. Education $31 3 payments
  3. Gift $18 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $732 57 payments
  2. RYBELSUS $667 53 payments
  3. TRELEGY ELLIPTA $589 44 payments
  4. FARXIGA $408 21 payments
  5. AIRSUPRA $371 15 payments
  6. SHINGRIX $339 22 payments
  7. Otezla $292 17 payments
  8. JARDIANCE $265 17 payments
  9. Repatha $257 15 payments
  10. Kerendia $236 13 payments
  11. Other $6,195 339 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 150 drugs

Part D claims

10,387

Median for Internal Medicine: 777

Drug cost

$906,302

Median for Internal Medicine: $73,373

Branded share of claims

18.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 92 $149,979
Eliquis Apixaban Brand 98 $90,435
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $76,514
Ozempic Semaglutide Brand 35 $50,859
Xarelto Rivaroxaban Brand 35 $50,320
Farxiga Dapagliflozin Propanediol Brand 33 $41,842
Linzess Linaclotide Brand 51 $34,270
Rybelsus Semaglutide Brand 28 $33,461
Januvia Sitagliptin Phosphate Brand 26 $29,284
Trulicity Dulaglutide Brand 11 $28,105

The 10 drugs with the highest cost, of 150 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$252,196

Of which drugs: $7,948

Medicare patients

272

Average age 73

Services billed

8,543

161 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Chronic kidney disease 43%
Diabetes 42%
Arthritis 36%
Ischemic heart disease 34%
Osteoporosis 18%
Depression 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 56 57 $4,634
Pcv20 vaccine im 90677 Office 11 11 $3,176
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 61 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$194 — —
SHINGRIX
$73 — —
VRAYLAR
$69 — —
Kerendia
$67 — —
BREZTRI
$66 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

435 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record